Oxford Biomedica H2 Earnings Call Highlights

Oxford Biomedica (LON: OXB) outlined a year of revenue growth, a return to operating EBITDA profitability, and continued expansion of its global viral vector CDMO network during its preliminary full-year 2025 results call. Management emphasized that 2025 reflected "sustained commercial momentum and disciplined execution," supported by rising demand across vector types and more client programs advancing